Bottom line
MIPXX vs MDHAX: the short answer
MIPXX (NYLI Money Market Fund) and MDHAX (NYLI MacKay Short Duration High Income Fund) are both money market funds.
MIPXX is cheaper at 0.47% vs 1.02% — a difference of $55 a year per $10,000 invested.
Over five years, MDHAX returned +4.1% a year vs +2.9% for MIPXX.
MDHAX has a front-end sales load of up to 3%; the other does not.
Updated Nov 19, 2026
MIPXX vs MDHAX side by side
| MIPXX | MDHAX | |
|---|---|---|
| Type | Money market fund | Mutual fund |
| Fund family | MFS | New York Life Investments |
| Category | Money Market | High-Yield Bond |
| Expense ratio | 0.47% | 1.02% |
| Annual cost per $10k | $47 | $102 |
| 10-yr cost on $10k (prospectus) | $591 | $1,531 |
| Max front load | 0% | 3% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +3.9% | +2.8% |
| 5-yr return (annualized) | +2.9% | +4.1% |
| 10-yr return (annualized) | +2.7% | +4.7% |
| Best quarter | — | — |
| Worst quarter | — | — |
| Net assets (fund) | — | $2.9B |
| Number of holdings | — | 462 |
| Portfolio turnover | — | 33% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MIPXX and MDHAX share none of their top holdings.
MIPXX top 10
MDHAX top 10
- Great Outdoors Group LLC — 1.10%
- Churchill Downs, Inc. — 1.00%
- Cloud Software Group LLC — 0.94%
- TransDigm, Inc. — 0.90%
- Organon & Co. — 0.88%
- TransDigm, Inc. — 0.82%
- Star Leasing Co. LLC — 0.74%
- Jazz Securities DAC — 0.74%
- SS&C Technologies, Inc. — 0.70%
- Core Scientific Finance I LLC — 0.67%
FAQ
What is the difference between MIPXX and MDHAX?
MIPXX (NYLI Money Market Fund) and MDHAX (NYLI MacKay Short Duration High Income Fund) are both money market funds. MIPXX is cheaper at 0.47% vs 1.02% — a difference of $55 a year per $10,000 invested.
Which is cheaper, MIPXX or MDHAX?
MIPXX has the lower expense ratio (0.47%).
Should I own both MIPXX and MDHAX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.